An electrochemically active device is provided for collecting and retaining a blood sample with at least a two-electrode member connected to conductive tracks. A receptor with an integral receptor-membrane arranged on the two-electrode member, to receive non-electrochemically active heamoglobin bioanalyte and its complexes from red blood cells (RBC) of said blood sample, through a lysing agent and convert the non-electrochemically active heamoglobin bioanalyte and its complexes, into an electrochemically active bioanalyte and its electrochemically active complexes. The present invention also provides a point-of-care biosensor incorporated with the device of the present invention and method of measuring for the detection and quantitative measurement of concentrations of haemoglobin (Hb), glycated haemoglobin (GHb), methaemoglobin (MetHb) and myoglobin, in reduced volumes of blood samples, by determining redox current values in the reduced volumes of blood samples.

A hemoglobin detecting method is executed by a mobile device having a hemoglobin detecting function. The mobile device includes a processor unit, a first light source that generates a first light beam, and a light detecting module that receives a second light beam that is generated when the first light beam travels through an analyte solution and is reflected. The light detecting module generates first to fourth intensity signals according to the second light beam, and the processor unit determines whether the absorption spectrum of the analyte solution matches a target spectrum. If the absorption spectrum of the analyte solution matches the target spectrum, the processor unit generates positive result information; otherwise, the processor unit generates negative result information. The mobile device provides a fast and accurate way to detect blood in a stool solution, which does not require collecting samples of stool or applying any chemical.

An electrochemically active device is provided for collecting and retaining a blood sample with at least a two-electrode member connected to conductive tracks. A receptor with an integral receptor-membrane arranged on the two-electrode member, to receive non-electrochemically active heamoglobin bioanalyte and its complexes from red blood cells (RBC) of said blood sample, through a lysing agent and convert the non-electrochemically active heamoglobin bioanalyte and its complexes, into an electrochemically active bioanalyte and its electrochemically active complexes. The present invention also provides a point-of-care biosensor incorporated with the device of the present invention and method of measuring for the detection and quantitative measurement of concentrations of haemoglobin (Hb), glycated haemoglobin (GHb), methaemoglobin (MetHb) and myoglobin, in reduced volumes of blood samples, by determining redox current values in the reduced volumes of blood samples.

A biochip compatible with very small blood sample volumes is used for delecting for detecting hemoglobin disorders and monitoring disorders associated with aberrant blood cell deformability and adhesion, including disease severity, upcoming pain crisis, treatment response, and treatment effectiveness in a clinically meaningful way.

An object of the present invention is to provide a hemoglobin measurement reagent and measurement method that allow for more accurate measurement of the amount of hemoglobin by suppressing a decrease in a measured value of hemoglobin triggered by the addition of haptoglobin. The reagent for measuring hemoglobin of the present invention includes: an insoluble carrier immobilizing an anti-hemoglobin antibody; and an insoluble carrier immobilizing an anti-haptoglobin antibody. The method for measuring hemoglobin in a specimen of the present invention includes: a step (1) of mixing a specimen with haptoglobin and forming a hemoglobin-haptoglobin complex to obtain a sample containing the hemoglobin-haptoglobin complex; and a step (2) of bringing the sample obtained in the step (1) into contact with the insoluble carrier immobilizing an anti-hemoglobin antibody and the insoluble carrier immobilizing an anti-haptoglobin antibody to cause immunoagglutination.

The present invention relates to methods for treating iron deficiency in a subject comprising noninvasively determining the hemoglobin level in the subject, and providing the subject with an iron supplement accordingly.

Artificial blood for a bloodstain pattern analysis includes water, an amino acid solution, bovine serum albumin, hemoglobin from bovine blood, potassium ferricyanide, sodium hyaluronate, sodium chloride, and tar color.

Electrochemical test sensors and analysis methods are described that reduce or eliminate the pre-treatment or dilution of blood samples prior to HbA1c analysis. Thus, a blood sample obtained from a blood draw or phlebotomy may be introduced to the electrochemical test sensor for HbA1c analysis. The described test sensors immobilize or deactivate incompatible reagents, enzymes, and antibodies so they do not substantially interfere with each other during the analysis. The test sensors also use heat to catalyze reactions that otherwise would proceed at too slow of a rate to be practical.

Hypermetabolic states that include cancer, infections, inflammations, mental illnesses, and chronic pain are sustained with ATP produced by aerobic glycolysis. Because of redundancies within this metabolic pathway, inhibition of aerobic glycolysis requires a combination drug therapy, which at the present time is optimal with 2-Deoxy-D-Glucose (2DG) and D-Lactic Acid Dimer (DLAD). Red blood cells exclusively derive energy from aerobic glycolysis, and spectrophotometric measurement of hemolysis can be utilized to monitor the effectiveness of drug combinations that inhibit aerobic glycolysis, particularly in hypermetabolic states. These measurements can be performed cheaply and easily in most health care facilities. Complete inhibition of aerobic glycolysis may necessitate red blood cell transfusion, but cells with mitochondria can produce sufficient ATP through lipid oxidation and amino acid metabolism to remain viable.

An apparatus for determining the mean corpuscular haemoglobin concentration (MCHC) in a whole blood sample includes a sample holder including an elongate sample chamber having an open end and a closed end. A holding member is adapted to receive and retain the sample holder. The holding member rotates may rotate about an axis of rotation. When the sample holder is received and retained by the holding member the sample chamber is substantially perpendicular to the axis of rotation. First and second light sources are positioned on one side of the sample holder and are configured to emit light in respective different frequencies. At least one light sensor is positioned on a second side of the sample holder, opposite from the first side, so that light from the light source may pass through the sample chamber, in at least one rotational position of the sample holder, and impinge on the light sensor.